Each cancer has a different combination of mutations in its DNA, and this is what makes a tumour unique.
The molecular tumour profiling establish, what we could call, a fingerprinting of each cancer.
There are several types of DNA mutations: single nucleotide variant (SNV), deletion or insertion of DNA nucleotides (indel), fusion of two DNA fragments to create an oncogene, and the amplification (copy/paste) of a same fragment of DNA (CNV). All these mutations can be detected by OncoDNA solutions.
In addition to DNA mutations, a tumour may also show many surface proteins that could help identify the best therapy. OncoDNA is a pioneer in analysing not only the DNA of the tumour but also the proteins. OncoDNA identify these proteins using a technique of tumour cell staining called (called immunohistochemistry)
Targeted therapies have become key in precision medicine. Their goal is to halt tumour progression by inhibiting the activity of specific targets related to tumor progression:
(1) Extracellular growth factors that promote the formation of new blood vessels (a process called angiogenesis). These blood vessels supply the cancer cells with oxygen and nutrients and are therefore crucial for tumour enlargement and invasion of new tissues.
(2) Transmembrane receptors. These receptors are located on the surface of tumor cells and bind to extracellular molecules (signals), such as growth factors. The receptors subsequently transmit the signal information to other molecules (proteins) inside of the cell.
(3) Intracellular proteins that receive the signal transmitted through the transmembrane receptors. They promote a variety of cellular processes, such as tumour growth, survival or invasion.
Many targeted therapies are currently under development.
Hormones are important molecules in our body that regulate many processes, such as growth, development and reproduction.
Hormonal therapies are drugs used to block the action or production of hormones in the body, thereby slowing or stopping the growth of certain cancers that are hormone-sensitive (meaning that they are dependent on a hormone for survival and/or growth). Hormone-sensitive tumors show hormone receptors on their surface, such as estrogen and progesterone receptors in breast cancer, or androgen receptor in prostate cancer.more info
One of the main roles of our immune system is to defend the body against infecting and other foreign agents by distinguishing
our body´s own cells from foreign elements. The principal immunologic cells are called leukocytes or white blood cells, and some examples include macrophages and lymphocytes (natural killer cells, T-cells and B-cells).
But the immune system not only provides a line of defense against foreign agents, it can also protect us against tumor cells. Unfortunately, cancer cells have several strategies to become "invisible" for the immune system and avoid in this way immune-mediated elimination.
The goal of immunotherapy is to mobilise the patient's own immune system against the disease. There are several kinds of immunotherapies, such as artificial monoclonal antibodies or immune checkpoint inhibitors. The latter ones bind to molecules that inhibit the immune system, blocking those immune-inhibitory molecules and reactivating the immune system.
OncoDEEP analyses solid biopsies from the primary tumour site or a metastasis by combining DNA sequencing (313 genes), immunohistochemistries to study protein expression and additional tests. This complete tumor profiling allows to predict patient response to approved or experimental targeted drugs, immunotherapies, hormonal therapies and chemotherapies.
OncoSTRAT&GO is an integrated approach that combines the analyses of a solid biopsy from the primary tumour site or a metastasis (by DNA sequencing (313 genes), immunohistochemistries and additional tests) with the analysis of a blood biopsy.
OncoSTRAT&GO establishes a complete genetic profile of the tumor, which can be used to identify sensitivity or resistance to targeted therapies, chemotherapies, hormonal therapies and immunotherapies.
OncoSELECT is a fast and minimally invasive analysis of circulating tumour DNA from a blood sample.
It is the perfect solution to identify therapeutic options for cancer patients not able to have their tumor biopsied or whose biopsy is too old. It can be used as a tool to detect treatment resistance to targeted therapies (before first-line to check the heterogeneity of the disease, or during/after treatment to check for acquired resistance mutations), as well as for monitoring cancer progression.
Our monitoring solution is a test based on the analysis of circulating tumour DNA. It is used to monitor the patient response to treatment and thus detect a possible recurrence of the disease.
The test is customised for each patient, as it contains specific mutations identified during previous genomic analysis.
OncoSHARE is a web platform with an active community of more than 13,000 patients and oncologists, through which your doctor can request tests and view the final report. The platform also allows you to get in contact with us and to pay for your molecular profiling test.
At OnDNA, we always want to stay on top, that's why we always try to keep up to date with the latest scientific news that may interest you, that's why we provide you with personalised information, you read what you need.read more news
A recent publication showed that OncoDNA provided information on available treatments in 92% of patients with advanced solid cancer. However, each cancer is different and it may also be that no alternative is found. The usefulness of the test will depend on your type of cancer, its severity, which treatments you have already received, and many other factors. Feel free to ask your oncologist to contact us to assess the possible benefits regarding your case.
After ordering the test that you need via the OncoSHARE web platform, your oncologist will receive a kit that he/she will use to send us your sample (tumour tissue specimen or/and blood sample). You will be asked to settle your invoice by credit card or bank transfer. Once we receive your payment and your sample, we will perform the analysis in our certified laboratory. Your oncologist will be notified as soon as the results are available (7 to 10 working days depending on the test), so that he/she can check the report with our therapeutic recommendations.
Our tests are designed to provide your oncologist with the most comprehensive information to make the best choice of treatment. However, cancer is a complex disease that evolves over time, and therefore it is very complex to predict the efficacy of a treatment. What we are doing is to provide you with the best possibilities of treatment based on scientific knowledge.
Our tests are reimbursed in a growing number of countries. The reimbursement depends on your public or private health insurance scheme, and either some or all our tests may be covered. Our solutions may also be available through certain research projects in which your oncologist may be taking part in.
In any case, talk to your oncologist and to your insurance provider fo additional information.